Indole Derivatives: A Versatile Scaffold in Modern Drug Discovery—An Updated Review on Their Multifaceted Therapeutic Applications (2020–2024)
Abstract
:1. Introduction
2. Biological Activities of Indole Derivatives
2.1. Anticancer Activity
2.1.1. Tubulin Polymerization Inhibitors
2.1.2. Protein Kinase Inhibitors
2.1.3. Bcl-2 Inhibitors
2.1.4. Carbonic Anhydrases IX and XII Inhibitors
2.1.5. Estrogen Receptor Modulators
2.1.6. HIF-1α Inhibitors
2.1.7. HDAC Inhibitors
2.1.8. LSD1 Inhibitors
2.1.9. IMPDH Inhibitors
2.1.10. Other Anticancer Mechanisms
2.2. Antimicrobial Activity
2.2.1. Antibacterial Activity
2.2.2. Antifungal Activity
2.2.3. Antiviral Activity
2.3. Anti-Inflammatory Activity
2.4. Antidiabetic Activity
2.5. In the Management of Neurodegenerative Diseases
2.5.1. Cholinesterase Inhibitors
2.5.2. Other Mechanisms
2.6. Antihypertensive Activity
3. Future Perspectives
4. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Smith, B.J.; Liu, R. A theoretical investigation of indole tautomers. J. Mol. Struct. Theochem 1999, 491, 211–222. [Google Scholar] [CrossRef]
- Kumar, S.; Ritika. A brief review of the biological potential of indole derivatives. Future J. Pharm. Sci. 2020, 6, 121. Available online: https://fjps.springeropen.com/articles/10.1186/s43094-020-00141-y (accessed on 29 August 2024). [CrossRef]
- Singh, T.P.; Singh, O.M. Recent Progress in Biological Activities of Indole and Indole Alkaloids. Mini Rev. Med. Chem. 2018, 18, 9–25. [Google Scholar] [CrossRef]
- Li, T.; Xu, H. Recent Progress of Bioactivities, Mechanisms of Action, Total Synthesis, Structural Modifications and Structure-activity Relationships of Indole Derivatives: A Review. Bentham Sci. 2022, 22, 2702–2725. Available online: https://www.eurekaselect.com/article/122049 (accessed on 29 August 2024).
- Kumari, A.; Singh, R.K. Medicinal chemistry of indole derivatives: Current to future therapeutic prospectives. Bioorganic Chem. 2019, 89, 103021. [Google Scholar] [CrossRef] [PubMed]
- Shamon, S.D.; Perez, M.I. Blood pressure-lowering efficacy of reserpine for primary hypertension. Cochrane Database Syst. Rev. 2016, 2016, CD007655. [Google Scholar] [CrossRef]
- Hoenders, H.J.R.; Bartels-Velthuis, A.A.; Vollbehr, N.K.; Bruggeman, R.; Knegtering, H.; de Jong, J.T.V.M. Natural Medicines for Psychotic Disorders. J. Nerv. Ment. Dis. 2018, 206, 81–101. [Google Scholar] [CrossRef]
- Steiger, H. Eating disorders and the serotonin connection: State, trait and developmental effects. J. Psychiatry Neurosci. 2004, 29, 20–29. [Google Scholar]
- Portas, C.M.; Bjorvatn, B.; Ursin, R. Serotonin and the sleep/wake cycle: Special emphasis on microdialysis studies. Prog. Neurobiol. 2000, 60, 13–35. [Google Scholar] [CrossRef]
- Alivisatos, S.G.A.; Papaphilis, A.D.; Ungar, F.; Seth, P.K. Chemical Nature of Binding of Serotonin in the Central Nervous System. Nature 1970, 226, 455–456. [Google Scholar] [CrossRef]
- Ferlazzo, N.; Andolina, G.; Cannata, A.; Costanzo, M.G.; Rizzo, V.; Currò, M.; Ientile, R.; Caccamo, D. Is Melatonin the Cornucopia of the 21st Century? Antioxidants 2020, 9, 1088. [Google Scholar] [CrossRef] [PubMed]
- Disorders, S. Role of Melatonin in the Management of Sleep and Circadian Disorders in the Context of Psychiatric Illness. Curr. Psychiatry Rep. 2022, 24, 623–634. Available online: https://link.springer.com/article/10.1007/s11920-022-01369-6 (accessed on 29 August 2024).
- Anticancer Potential of Indole Derivatives: An Update. Available online: https://www.degruyter.com/document/doi/10.1515/psr-2021-0028/html (accessed on 29 August 2024).
- Kaur, K.; Jaitak, V. Recent Development in Indole Derivatives as Anticancer Agents for Breast Cancer. Anti-Cancer Agents Med. Chem. 2019, 19, 962–983. [Google Scholar] [CrossRef] [PubMed]
- Sunitinib in the Treatment of Renal Cell Carcinoma: An Update on Recent Evidence—PMC. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896861/ (accessed on 29 August 2024).
- Casali, P.G.; Garrett, C.R.; Blackstein, M.E.; Shah, M.; Verweij, J.; McArthur, G.; Judson, I.; Li, J.; Baum, C.M.; Demetri, G.D. Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. JCO 2006, 24, 9513. [Google Scholar] [CrossRef]
- Qin, H.-L.; Liu, J.; Fang, W.-Y.; Ravindar, L.; Rakesh, K.P. Indole-based derivatives as potential antibacterial activity against methicillin-resistance Staphylococcus aureus (MRSA). Eur. J. Med. Chem. 2020, 194, 112245. [Google Scholar] [CrossRef]
- Selsted, M.E.; Novotny, M.J.; Morris, W.L.; Tang, Y.Q.; Smith, W.; Cullor, J.S. Indolicidin, a novel bactericidal tridecapeptide amide from neutrophils. J. Biol. Chem. 1992, 267, 4292–4295. [Google Scholar] [CrossRef]
- Yaikhan, T.; Chuerboon, M.; Tippayatham, N.; Atimuttikul, N.; Nuidate, T.; Yingkajorn, M.; Tun, A.W.; Buncherd, H.; Tansila, N. Indole and Derivatives Modulate Biofilm Formation and Antibiotic Tolerance of Klebsiella pneumoniae. Indian J. Microbiol. 2019, 59, 460–467. [Google Scholar] [CrossRef]
- Nalamachu, S.; Wortmann, R. Role of indomethacin in acute pain and inflammation management: A review of the literature. Postgrad. Med. 2014, 126, 92–97. [Google Scholar] [CrossRef]
- Ahmad, A.; Biersack, B.; Li, Y.; Kong, D.; Bao, B.; Schobert, R.; Padhye, S.B.; Sarkar, F.H. Targeted Regulation of PI3K/Akt/mTOR/NF-κB Signaling by Indole Compounds and their Derivatives: Mechanistic Details and Biological Implications for Cancer Therapy. Available online: https://www.eurekaselect.com/article/54078 (accessed on 29 August 2024).
- Design, Synthesis, Biological Evaluation and Docking Study of Novel Indole-2-Amide as Anti-Inflammatory Agents with Dual Inhibition of COX and 5-LOX—ScienceDirect. Available online: https://www.sciencedirect.com/science/article/pii/S0223523419306257 (accessed on 29 August 2024).
- Philoppes, J.N.; Abdelgawad, M.A.; Abourehab, M.A.S.; Sebak, M.; Darwish, M.A.; Lamie, P.F. Novel N-methylsulfonyl-indole derivatives: Biological activity and COX-2/5-LOX inhibitory effect with improved gastro protective profile and reduced cardio vascular risks. J. Enzyme Inhib. Med. Chem. 2023, 38, 246–266. [Google Scholar] [CrossRef]
- Golightly, L.K. Pindolol: A review of its pharmacology, pharmacokinetics, clinical uses, and adverse effects. Pharmacotherapy 1982, 2, 134–147. [Google Scholar] [CrossRef]
- Ruffolo, R.R.; Feuerstein, G.Z. Pharmacology of carvedilol: Rationale for use in hypertension, coronary artery disease, and congestive heart failure. Cardiovasc. Drugs Ther. 1997, 1 (Suppl. 11), 247–256. [Google Scholar] [CrossRef] [PubMed]
- Shaw, K.; Turner, J.; Del Mar, C. Tryptophan and 5-Hydroxytryptophan for depression. Cochrane Database Syst. Rev. 2002, 1, CD003198. [Google Scholar] [CrossRef] [PubMed]
- Hendricks, E.J. Off-label drugs for weight management. DMSO 2017, 10, 223–234. [Google Scholar] [CrossRef] [PubMed]
- Ferrari, M.D.; Saxena, P.R. Clinical effects and mechanism of action of sumatriptan in migraine. Clin. Neurol. Neurosurg. 1992, 94, S73–S77. [Google Scholar] [CrossRef]
- Moore, D. Panobinostat (Farydak): A Novel Option for the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma. Pharm. Ther. 2016, 41, 296–300. [Google Scholar]
- Simpson, K.; Spencer, C.M.; McClellan, K.J. Tropisetron: An update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2000, 59, 1297–1315. [Google Scholar] [CrossRef]
- Langtry, H.D.; Clissold, S.P. Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson’s disease. Drugs 1990, 39, 491–506. [Google Scholar] [CrossRef]
- Xu, B.; Kang, B.; Chen, J.; Li, S.; Zhou, J. Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria. Blood Rev. 2024, 66, 101210. [Google Scholar] [CrossRef]
- Scott, L.J.; Perry, C.M. Delavirdine: A review of its use in HIV infection. Drugs 2000, 60, 1411–1444. [Google Scholar] [CrossRef]
- Wang, S.-M.; Han, C.; Lee, S.-J.; Patkar, A.A.; Masand, P.S.; Pae, C.-U. Vilazodone for the Treatment of Depression: An Update. Chonnam. Med. J. 2016, 52, 91–100. [Google Scholar] [CrossRef]
- Yavropoulou, M.P.; Makras, P.; Anastasilakis, A.D. Bazedoxifene for the treatment of osteoporosis. Expert Opin. Pharmacother. 2019, 20, 1201–1210. [Google Scholar] [CrossRef] [PubMed]
- Rains, C.P.; Bryson, H.M.; Fitton, A. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Drugs 1995, 49, 255–279. [Google Scholar] [CrossRef] [PubMed]
- Curran, M.P.; Perry, C.M. Cabergoline: A review of its use in the treatment of Parkinson’s disease. Drugs 2004, 64, 2125–2141. [Google Scholar] [CrossRef] [PubMed]
- Bellamy, N. Etodolac in the management of pain: A clinical review of a multipurpose analgesic. Inflammopharmacology 1997, 5, 139–152. [Google Scholar] [CrossRef] [PubMed]
- Latest Global Cancer Data: Cancer Burden Rises to 19.3 Million New Cases and 10.0 Million Cancer Deaths in 2020. Available online: https://www.iarc.who.int/news-events/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020 (accessed on 29 August 2024).
- Hashem, H.; Hassan, A.; Abdelmagid, W.M.; Habib, A.G.K.; Abdel-Aal, M.A.A.; Elshamsy, A.M.; El Zawily, A.; Radwan, I.T.; Bräse, S.; Abdel-Samea, A.S.; et al. Synthesis of New Thiazole-Privileged Chalcones as Tubulin Polymerization Inhibitors with Potential Anticancer Activities. Pharmaceuticals 2024, 17, 1154. [Google Scholar] [CrossRef]
- Al-Wahaibi, L.H.; Elshamsy, A.M.; Ali, T.F.S.; Youssif, B.G.M.; Bräse, S.; Abdel-Aziz, M.; El-Koussi, N.A. Design and Synthesis of New Dihydropyrimidine Derivatives with a Cytotoxic Effect as Dual EGFR/VEGFR-2 Inhibitors. ACS Omega 2024, 9, 34358–34369. [Google Scholar] [CrossRef]
- Mohammed, H.H.H.; El-Hafeez, A.A.A.; Abbas, S.H.; Abdelhafez, E.-S.M.N.; Abuo-Rahma, G.E.-D.A. New antiproliferative 7-(4-(N-substituted carbamoylmethyl)piperazin-1-yl) derivatives of ciprofloxacin induce cell cycle arrest at G2/M phase. Bioorg. Med. Chem. 2016, 24, 4636–4646. [Google Scholar] [CrossRef]
- Mohammed, H.H.H.; Abbas, S.H.; Hayallah, A.M.; Abuo-Rahma, G.E.-D.A.; Mostafa, Y.A. Novel urea linked ciprofloxacin-chalcone hybrids having antiproliferative topoisomerases I/II inhibitory activities and caspases-mediated apoptosis. Bioorg. Chem. 2021, 106, 104422. [Google Scholar] [CrossRef]
- Mohammed, H.H.H.; El-Hafeez, A.A.A.; Ebeid, K.; Mekkawy, A.I.; Abourehab, M.A.S.; Wafa, E.I.; Alhaj-Suliman, S.O.; Salem, A.K.; Ghosh, P.; Abuo-Rahma, G.E.-D.A.; et al. New,3-triazole linked ciprofloxacin-chalcones induce DNA damage by inhibiting human topoisomerase I& II and tubulin polymerization. J. Enzym. Inhib. Med. Chem. 2022, 37, 1346–1363. [Google Scholar] [CrossRef]
- Alhaj-Suliman, S.O.; Naguib, Y.W.; Wafa, E.I.; Saha, S.; Ebeid, K.; Meng, X.; Mohammed, H.H.; Abuo-Rahma, G.E.-D.A.; Yang, S.; Salem, A.K. A ciprofloxacin derivative with four mechanisms of action overcomes paclitaxel resistance in p53-mutant and MDR1 gene-expressing type II human endometrial cancer. Biomaterials 2023, 296, 122093. [Google Scholar] [CrossRef]
- Al-Hakkani, M.F.; Ahmed, N.; Abbas, A.A.; Hassan, M.H.A.; Aziz, H.A.; Elshamsy, A.M.; Khalifa, H.O.; Abdelshakour, M.A.; Saddik, M.S.; Elsayed, M.M.A.; et al. Synthesis, Physicochemical Characterization using a Facile Validated HPLC Quantitation Analysis Method of 4-Chloro-phenylcarbamoyl-methyl Ciprofloxacin and Its Biological Investigations. Int. J. Mol. Sci. 2023, 24, 14818. [Google Scholar] [CrossRef] [PubMed]
- Naguib, Y.W.; Alhaj-Suliman, S.O.; Wafa, E.I.; Saha, S.; Ebeid, K.; Mohammed, H.H.H.; Abdel-Rahman, S.A.; Abuo-Rahma, G.E.-D.A.; Geary, S.M.; Salem, A.K. Ciprofloxacin Derivative-Loaded Nanoparticles Synergize with Paclitaxel Against Type II Human Endometrial Cancer. Small 2023, e2302931. [Google Scholar] [CrossRef] [PubMed]
- Indole-Based Tubulin Inhibitors: Binding Modes and SARs Investigations—PMC. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911766/ (accessed on 29 August 2024).
- Kinase Inhibitor Indole Derivatives as Anticancer Agents: A Patent Review—PubMed. Available online: https://pubmed.ncbi.nlm.nih.gov/27697069/ (accessed on 29 August 2024).
- A Detail Survey and Analysis of Selectivity Criteria for Indole-Based Histone Deacetylase 8 (HDAC8) Inhibitors—ScienceDirect. Available online: https://www.sciencedirect.com/science/article/pii/S0022286022016192 (accessed on 29 August 2024).
- Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy—PubMed. Available online: https://pubmed.ncbi.nlm.nih.gov/36551271/ (accessed on 29 August 2024).
- Shuai, W.; Wang, G.; Zhang, Y.; Bu, F.; Zhang, S.; Miller, D.D.; Li, W.; Ouyang, L.; Wang, Y. Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy. J. Med. Chem. 2021, 64, 7963–7990. Available online: https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00100 (accessed on 29 August 2024). [CrossRef] [PubMed]
- Khwaja, S.; Kumar, K.; Das, R.; Negi, A.S. Microtubule associated proteins as targets for anticancer drug development. Bioorganic Chem. 2021, 116, 105320. [Google Scholar] [CrossRef] [PubMed]
- Mollinedo, F.; Gajate, C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003, 8, 413–450. [Google Scholar] [CrossRef]
- Lobert, S.; Vulevic, B.; Correia, J.J. Interaction of Vinca Alkaloids with Tubulin: A Comparison of Vinblastine, Vincristine, and Vinorelbine. Biochemistry 1996, 35, 6806–6814. Available online: https://pubs.acs.org/doi/10.1021/bi953037i (accessed on 29 August 2024). [CrossRef]
- Hawash, M.; Kahraman, D.C.; Olgac, A.; Ergun, S.G.; Hamel, E.; Cetin-Atalay, R.; Baytas, S.N. Design and synthesis of novel substituted indole-acrylamide derivatives and evaluation of their anti-cancer activity as potential tubulin-targeting agents. J. Mol. Struct. 2022, 1254, 132345. [Google Scholar] [CrossRef]
- Shi, L.; Yang, S.; Chang, J.; Zhang, Y.; Liu, W.; Zeng, J.; Meng, J.; Zhang, R.; Wang, C.; Xing, D. Design, synthesis and biological evaluation of 9-aryl-5H-pyrido[4,3-b]indole derivatives as potential tubulin polymerization inhibitors. Front. Chem. 2022, 10, 1004835. [Google Scholar] [CrossRef]
- Song, J.; Guan, Y.-F.; Liu, W.-B.; Song, C.-H.; Tian, X.-Y.; Zhu, T.; Fu, X.-J.; Qi, Y.-Q.; Zhang, S.-Y. Discovery of novel coumarin-indole derivatives as tubulin polymerization inhibitors with potent anti-gastric cancer activities. Eur. J. Med. Chem. 2022, 238, 114467. [Google Scholar] [CrossRef]
- Yan, J.; Xu, Y.; Jin, X.; Zhang, Q.; Ouyang, F.; Han, L.; Zhan, M.; Li, X.; Liang, B.; Huang, X. Structure modification and biological evaluation of indole-chalcone derivatives as anti-tumor agents through dual targeting tubulin and TrxR. Eur. J. Med. Chem. 2022, 227, 113897. [Google Scholar] [CrossRef]
- Ren, W.; Deng, Y.; Ward, J.D.; Vairin, R.; Bai, R.; Wanniarachchi, H.I.; Hamal, K.B.; Tankoano, P.E.; Tamminga, C.S.; Bueno, L.M.A.; et al. Synthesis and biological evaluation of structurally diverse 6-aryl-3-aroyl-indole analogues as inhibitors of tubulin polymerization. Eur. J. Med. Chem. 2024, 263, 115794. [Google Scholar] [CrossRef] [PubMed]
- Reddy, T.S.; Rai, S.; Koppula, S.K. Synthesis of indole-tetrazole coupled aromatic amides; In vitro anticancer activity, in vitro tubulin polymerization inhibition assay and in silico studies. J. Mol. Struct. 2022, 1267, 133556. [Google Scholar] [CrossRef]
- Boda, S.; Nukala, S.K.; Manchal, R. Synthesis of Some New Indole-1,3,4-Oxadiazole Hybrids as Tubulin Polymerization Inhibitors. Russ. J. Bioorg. Chem. 2022, 48, S136–S143. [Google Scholar] [CrossRef]
- Hurysz, B.; Evans, B.A.; Laryea, R.N.; Boyer, B.E.; Coburn, T.E.; Dexter, M.S.; Edwards, M.A.; Faulkner, G.V.; Huss, R.L.; Lafferty, M.M.; et al. Synthesis, modeling, and biological evaluation of anti-tubulin indole-substituted furanones. Bioorg. Med. Chem. Lett. 2023, 90, 129347. [Google Scholar] [CrossRef]
- Liang, B.; Zou, Q.; Yu, L.; Wang, Y.; Yan, J.; Huang, B. Novel Indole-Containing Hybrids Derived from Millepachine: Synthesis, Biological Evaluation and Antitumor Mechanism Study. Molecules 2023, 28, 1481. [Google Scholar] [CrossRef]
- Wang, H.; Nie, C.; Luo, M.; Bai, Q.; Yao, Z.; Lv, H.; Chen, B.; Wang, J.; Xu, W.; Wang, S.; et al. Novel GSH-responsive prodrugs derived from indole-chalcone and camptothecin trigger apoptosis and autophagy in colon cancer. Bioorg. Chem. 2024, 143, 107056. [Google Scholar] [CrossRef]
- Bhullar, K.S.; Lagarón, N.O.; McGowan, E.M.; Parmar, I.; Jha, A.; Hubbard, B.P.; Rupasinghe, H.P.V. Kinase-targeted cancer therapies: Progress, challenges and future directions. Mol. Cancer 2018, 17, 48. [Google Scholar] [CrossRef]
- Neagu, M.; Constantin, C. Signal Transduction in Immune Cells and Protein Kinases. In Protein Kinase-Mediated Decisions between Life and Death; Engin, A.B., Engin, A., Eds.; Springer International Publishing: Cham, Switzerland, 2021; pp. 133–149. [Google Scholar] [CrossRef]
- Kannaiyan, R.; Mahadevan, D. A comprehensive review of protein kinase inhibitors for cancer therapy. Expert. Rev. Anticancer. Ther. 2018, 18, 1249–1270. [Google Scholar] [CrossRef]
- Zubair, T.; Bandyopadhyay, D. Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities. Int. J. Mol. Sci. 2023, 24, 2651. [Google Scholar] [CrossRef]
- Gomaa, H.A.M.; Shaker, M.E.; Alzarea, S.I.; Hendawy, O.M.; Mohamed, F.A.M.; Gouda, A.M.; Ali, A.T.; Morcoss, M.M.; Abdelrahman, M.H.; Trembleau, L.; et al. Optimization and SAR investigation of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as EGFR and BRAFV600E dual inhibitors with potent antiproliferative and antioxidant activities. Bioorg. Chem. 2022, 120, 105616. [Google Scholar] [CrossRef]
- Shawish, I.; Nafie, M.S.; Barakat, A.; Aldalbahi, A.; Al-Rasheed, H.H.; Ali, M.; Alshaer, W.; Al Zoubi, M.; Al Ayoubi, S.; De la Torre, B.G.; et al. Pyrazolyl-s-triazine with indole motif as a novel of epidermal growth factor receptor/cyclin-dependent kinase 2 dual inhibitors. Front. Chem. 2022, 10, 1078163. [Google Scholar] [CrossRef] [PubMed]
- Khalilullah, H.; Agarwal, D.K.; Ahsan, M.J.; Jadav, S.S.; Mohammed, H.A.; Khan, M.A.; Mohammed, S.A.A.; Khan, R. Synthesis and Anti-Cancer Activity of New Pyrazolinyl-Indole Derivatives: Pharmacophoric Interactions and Docking Studies for Identifying New EGFR Inhibitors. Int. J. Mol. Sci. 2022, 23, 6548. [Google Scholar] [CrossRef] [PubMed]
- Yu, G.-X.; Hu, Y.; Zhang, W.-X.; Tian, X.-Y.; Zhang, S.-Y.; Zhang, Y.; Yuan, S.; Song, J. Design, Synthesis and Biological Evaluation of [1,2,4]Triazolo[1,5-a]pyrimidine Indole Derivatives against Gastric Cancer Cells MGC-803 via the Suppression of ERK Signaling Pathway. Molecules 2022, 27, 4996. [Google Scholar] [CrossRef] [PubMed]
- Mebratu, Y.; Tesfaigzi, Y. How ERK1/2 Activation Controls Cell Proliferation and Cell Death Is Subcellular Localization the Answer? Cell Cycle 2009, 8, 1168–1175. [Google Scholar] [CrossRef]
- Guo, Y.-J.; Pan, W.-W.; Liu, S.-B.; Shen, Z.-F.; Xu, Y.; Hu, L.-L. ERK/MAPK signalling pathway and tumorigenesis (Review). Exp. Ther. Med. 2020, 19, 1997–2007. [Google Scholar] [CrossRef]
- Cho, D.; Mier, J.W.; Atkins, M.B. PI3K/Akt/mTOR Pathway. In Renal Cell Carcinoma: Molecular Targets and Clinical Applications; Bukowski, R.M., Figlin, R.A., Motzer, R.J., Eds.; Humana Press: Totowa, NJ, USA, 2009; pp. 267–285. [Google Scholar] [CrossRef]
- Peng, Y.; Wang, Y.; Zhou, C.; Mei, W.; Zeng, C. PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? Front. Oncol. 2022, 12, 819128. [Google Scholar] [CrossRef]
- Qin, J.; Sun, X.; Ma, Y.; Cheng, Y.; Ma, Q.; Jing, W.; Qu, S.; Liu, L. Design, synthesis and biological evaluation of novel 1,3,4,9-tetrahydropyrano[3,4-b]indoles as potential treatment of triple negative breast cancer by suppressing PI3K/AKT/mTOR pathway. Bioorg. Med. Chem. 2022, 55, 116594. [Google Scholar] [CrossRef]
- Tyagi, R.; Yadav, K.; Khanna, A.; Mishra, S.K.; Sagar, R. Efficient synthesis of indole-chalcones based glycohybrids and their anticancer activity. Bioorg. Med. Chem. 2024, 109, 117778. [Google Scholar] [CrossRef]
- Ibrahim, M.S.; Farag, B.; Al-Humaidi, J.Y.; Zaki, M.E.A.; Fathalla, M.; Gomha, S.M. Mechanochemical Synthesis and Molecular Docking Studies of New Azines Bearing Indole as Anticancer Agents. Molecules 2023, 28, 3869. [Google Scholar] [CrossRef]
- Perike, N.; Edigi, P.K.; Nirmala, G.; Thumma, V.; Bujji, S.; Naikal, P.S. Synthesis, Anticancer Activity and Molecular Docking Studies of Hybrid Molecules Containing Indole-Thiazolidinedione-Triazole Moieties. ChemistrySelect 2022, 7, e202203778. [Google Scholar] [CrossRef]
- Parthiban, A.; Sivasankar, R.; Rajdev, B.; Asha, R.N.; Jeyakumar, T.C.; Periakaruppan, R.; Naidu, V. Synthesis, in vitro, in silico and DFT studies of indole curcumin derivatives as potential anticancer agents. J. Mol. Struct. 2022, 1270, 133885. [Google Scholar] [CrossRef]
- Xu, J.; Dong, X.; Huang, D.C.S.; Xu, P.; Zhao, Q.; Chen, B. Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers. Cancers 2023, 15, 4957. [Google Scholar] [CrossRef] [PubMed]
- Qian, S.; Wei, Z.; Yang, W.; Huang, J.; Yang, Y.; Wang, J. The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front. Oncol. 2022, 12, 985363. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Z.; Hou, L.; Bai, L.; Pei, J.; Zhao, S.; Luan, S.; Liu, D.; Huang, M.; Zhao, L. Discovery and structure-activity relationship studies of novel Bcl-2/Mcl-1 dual inhibitors with indole scaffold. Bioorg. Chem. 2022, 125, 105845. [Google Scholar] [CrossRef]
- Liu, Y.; Li, J.; Zhou, G.; Zhang, J.; Teng, Y.; Bai, Z.; Liu, T. Design, synthesis and anticancer activity studies of novel indole derivatives as Bcl-2/Mcl-1 dual inhibitors. Med. Chem. Res. 2023, 32, 99–108. [Google Scholar] [CrossRef]
- Almehdi, A.M.; Soliman, S.S.M.; El-Shorbagi, A.-N.A.; Westwell, A.D.; Hamdy, R. Design, Synthesis, and Potent Anticancer Activity of Novel Indole-Based Bcl-2 Inhibitors. Int. J. Mol. Sci. 2023, 24, 14656. [Google Scholar] [CrossRef]
- Hassan, M.I.; Shajee, B.; Waheed, A.; Ahmad, F.; Sly, W.S. Structure, function and applications of carbonic anhydrase isozymes. Bioorg. Med. Chem. 2013, 21, 1570–1582. [Google Scholar] [CrossRef]
- Hashem, H.H.H. Design, synthesis, and molecular docking of novel urea linked 1,2,3-triazole-benzenesulfonamide hybrid as potential carbonic anhydrase inhibitors. J. Adv. Biomed. Pharm. Sci. 2024, 7, 53–59. [Google Scholar] [CrossRef]
- Pastorekova, S.; Gillies, R.J. The role of carbonic anhydrase IX in cancer development: Links to hypoxia, acidosis, and beyond. Cancer Metastasis Rev. 2019, 38, 65–77. [Google Scholar] [CrossRef]
- Lee, S.-H.; Griffiths, J.R. How and Why Are Cancers Acidic? Carbonic Anhydrase IX and the Homeostatic Control of Tumour Extracellular pH. Cancers 2020, 12, 1616. [Google Scholar] [CrossRef]
- Kopecka, J.; Campia, I.; Jacobs, A.; Frei, A.P.; Ghigo, D.; Wollscheid, B.; Riganti, C. Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells. Oncotarget 2015, 6, 6776–6793. [Google Scholar] [CrossRef] [PubMed]
- Kciuk, M.; Gielecińska, A.; Mujwar, S.; Mojzych, M.; Marciniak, B.; Drozda, R.; Kontek, R. Targeting carbonic anhydrase IX and XII isoforms with small molecule inhibitors and monoclonal antibodies. J. Enzym. Inhib. Med. Chem. 2022, 37, 1278–1298. [Google Scholar] [CrossRef] [PubMed]
- Krasavin, M.; Kalinin, S.; Sharonova, T.; Supuran, C.T. Inhibitory activity against carbonic anhydrase IX and XII as a candidate selection criterion in the development of new anticancer agents. J. Enzym. Inhib. Med. Chem. 2020, 35, 1555–1561. [Google Scholar] [CrossRef] [PubMed]
- Singh, P.; Goud, N.S.; Swain, B.; Sahoo, S.K.; Choli, A.; Angeli, A.; Kushwah, B.S.; Yaddanapudi, V.M.; Supuran, C.T.; Arifuddin, M. Synthesis of a new series of quinoline/pyridine indole-3-sulfonamide hybrids as selective carbonic anhydrase IX inhibitors. Bioorganic Med. Chem. Lett. 2022, 70, 128809. [Google Scholar] [CrossRef] [PubMed]
- Demir-Yazıcı, K.; Trawally, M.; Bua, S.; Öztürk-Civelek, D.; Akdemir, A.; Supuran, C.T.; Güzel-Akdemir, Ö. Novel 2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide based thiosemicarbazides as potent and selective inhibitors of tumor-associated human carbonic anhydrase IX and XII: Synthesis, cytotoxicity, and molecular modelling studies. Bioorg. Chem. 2024, 144, 107096. [Google Scholar] [CrossRef]
- Nguyen, P.L.; Elkamhawy, A.; Choi, Y.H.; Lee, C.H.; Lee, K.; Cho, J. Suppression of Tumor Growth and Cell Migration by Indole-Based Benzenesulfonamides and Their Synergistic Effects in Combination with Doxorubicin. Int. J. Mol. Sci. 2022, 23, 9903. [Google Scholar] [CrossRef]
- Liu, Y.; Ma, H.; Yao, J. ERα, A Key Target for Cancer Therapy: A Review. Onco Targets Ther. 2020, 13, 2183–2191. [Google Scholar] [CrossRef]
- Sreenatha, V.; Srinivasa, S.M.; Prasad, K.J.R. Design, synthesis, bioevaluation, DFT, docking, and molecular dynamic simulation for selected novel 1,3,4-Oxadiazole—Indole derivatives hybrid against estrogen receptor alpha. J. Mol. Struct. 2022, 1269, 133789. [Google Scholar] [CrossRef]
- Kaur, K.; Verma, H.; Gangwar, P.; Jangid, K.; Dhiman, M.; Kumar, V.; Jaitak, V. Design, synthesis, in silico and biological evaluation of new indole based oxadiazole derivatives targeting estrogen receptor alpha. Bioorg. Chem. 2024, 147, 107341. [Google Scholar] [CrossRef]
- Hu, C.-J.; Wang, L.-Y.; Chodosh, L.A.; Keith, B.; Simon, M.C. Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation. Mol. Cell Biol. 2003, 23, 9361–9374. [Google Scholar] [CrossRef]
- Qannita, R.A.; Alalami, A.I.; Harb, A.A.; Aleidi, S.M.; Taneera, J.; Abu-Gharbieh, E.; El-Huneidi, W.; Saleh, M.A.; Alzoubi, K.H.; Semreen, M.H.; et al. Targeting Hypoxia-Inducible Factor-1 (HIF-1) in Cancer: Emerging Therapeutic Strategies and Pathway Regulation. Pharmaceuticals 2024, 17, 195. [Google Scholar] [CrossRef] [PubMed]
- Bui, B.P.; Nguyen, P.L.; Lee, K.; Cho, J. Hypoxia-Inducible Factor-1: A Novel Therapeutic Target for the Management of Cancer, Drug Resistance, and Cancer-Related Pain. Cancers 2022, 14, 6054. [Google Scholar] [CrossRef] [PubMed]
- Keskin, S.; Doğan, Ş.D.; Gündüz, M.G.; Aleksic, I.; Vojnovic, S.; Lazic, J.; Nikodinovic-Runic, J. Indole-based hydrazone derivatives: Synthesis; cytotoxicity assessment, and molecular modeling studies. J. Mol. Struct. 2022, 1270, 133936. [Google Scholar] [CrossRef]
- Rahman, A.; Prashanth, N.; Nippu, B.N.; Kumaraswamy, H.M.; Rajeshwara, A.N.; Satyanarayan, N.D. Synthesis and anticancer screening of some novel Pd-catalysed 3-methyl indole based analogues on Mia PaCa-2 cell line. J. Mol. Struct. 2022, 1264, 133211. [Google Scholar] [CrossRef]
- Ropero, S.; Esteller, M. The role of histone deacetylases (HDACs) in human cancer. Mol. Oncol. 2007, 1, 19–25. [Google Scholar] [CrossRef] [PubMed]
- Liang, T.; Wang, F.; Elhassan, R.M.; Cheng, Y.; Tang, X.; Chen, W.; Fang, H.; Hou, X. Targeting histone deacetylases for cancer therapy: Trends and challenges. Acta Pharm. Sin. B 2023, 13, 2425–2463. [Google Scholar] [CrossRef]
- Jiang, B.-E.; Hu, J.; Liu, H.; Liu, Z.; Wen, Y.; Liu, M.; Zhang, H.-K.; Pang, X.; Yu, L.-F. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors. Eur. J. Med. Chem. 2022, 227, 113893. [Google Scholar] [CrossRef]
- Kim, D.; Kim, K.I.; Baek, S.H. Roles of lysine-specific demethylase 1 (LSD1) in homeostasis and diseases. J. Biomed. Sci. 2021, 28, 41. [Google Scholar] [CrossRef]
- Yang, F.-F.; Xu, X.-L.; Hu, T.; Liu, J.-Q.; Zhou, J.-Z.; Ma, L.-Y.; Liu, H.-M. Lysine-Specific Demethylase 1 Promises to Be a Novel Target in Cancer Drug Resistance: Therapeutic Implications. J. Med. Chem. 2023, 66, 4275–4293. [Google Scholar] [CrossRef]
- Zhang, X.; Sun, Y.; Huang, H.; Wang, X.; Wu, T.; Yin, W.; Li, X.; Wang, L.; Gu, Y.; Zhao, D.; et al. Identification of novel indole derivatives as highly potent and efficacious LSD1 inhibitors. Eur. J. Med. Chem. 2022, 239, 114523. [Google Scholar] [CrossRef]
- Hedstrom, L. IMP Dehydrogenase: Structure, Mechanism and Inhibition. Chem. Rev. 2009, 109, 2903–2928. [Google Scholar] [CrossRef] [PubMed]
- Naffouje, R.; Grover, P.; Yu, H.; Sendilnathan, A.; Wolfe, K.; Majd, N.; Smith, E.P.; Takeuchi, K.; Senda, T.; Kofuji, S.; et al. Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story. Cancers 2019, 11, 1346. [Google Scholar] [CrossRef]
- Jia, H.-W.; Yang, H.-L.; Xiong, Z.-L.; Deng, M.-H.; Wang, T.; Liu, Y.; Cheng, M. Design, synthesis and antitumor activity evaluation of novel indole acrylamide derivatives as IMPDH inhibitors. Bioorg. Chem. 2022, 129, 106213. [Google Scholar] [CrossRef]
- Lee, C.G.; Park, G.-Y.; Han, Y.K.; Lee, J.H.; Chun, S.H.; Park, H.-Y.; Lim, K.-H.; Kim, E.-G.; Choi, Y.-J.; Yang, K.; et al. Roles of 14-3-3η in mitotic progression and its potential use as a therapeutic target for cancers. Oncogene 2013, 32, 1560–1569. [Google Scholar] [CrossRef]
- Aseervatham, J. Interactions between 14-3-3 Proteins and Actin Cytoskeleton and Its Regulation by microRNAs and Long Non-Coding RNAs in Cancer. Endocrines 2022, 3, 665–702. [Google Scholar] [CrossRef]
- Gao, Z.; Fan, T.; Chen, L.; Yang, M.; Wong, V.K.W.; Chen, D.; Liu, Z.; Zhou, Y.; Wu, W.; Qiu, Z.; et al. Design, synthesis and antitumor evaluation of novel 1H-indole-2-carboxylic acid derivatives targeting 14-3-3η protein. Eur. J. Med. Chem. 2022, 238, 114402. [Google Scholar] [CrossRef]
- Yao, C.-H.; Wu, M.-H.; Chang, P.-W.; Wu, S.-H.; Song, J.-S.; Huang, H.-H.; Chen, Y.-C.; Lee, J.-C. Design, synthesis, and anticancer evaluation of 1-benzo[1,3]dioxol-5-yl-3-N-fused heteroaryl indoles. Mol. Divers 2024, 28, 595–608. [Google Scholar] [CrossRef] [PubMed]
- Deng, H.; Huang, M.; Liu, H.; Zhang, H.; Liu, L.; Gao, B.; Li, X.; Li, J.; Niu, Q.; Zhang, Z.; et al. Development of a series of novel Mcl-1 inhibitors bearing an indole carboxylic acid moiety. Bioorg. Chem. 2022, 127, 106018. [Google Scholar] [CrossRef] [PubMed]
- Qin, J.; Chen, X.; Liu, W.; Chen, J.; Liu, W.; Xia, Y.; Li, Z.; Li, M.; Wang, S.; Yuan, Q.; et al. Discovery of 5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole-2-carboxamide derivatives as novel anti-cancer agents targeting Nur77. Eur. J. Med. Chem. 2022, 244, 114849. [Google Scholar] [CrossRef]
- Guidetti, L.; Castelli, R.; Zappia, A.; Ferrari, F.R.; Giorgio, C.; Barocelli, E.; Pagliaro, L.; Vento, F.; Roti, G.; Scalvini, L.; et al. Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line. Eur. J. Med. Chem. 2024, 276, 116681. [Google Scholar] [CrossRef]
- Ramle, A.Q.; Chan, N.N.M.Y.; Ng, M.P.; Tan, C.H.; Sim, K.S.; Tiekink, E.R.T.; Fei, C.C. Structural insights and cytotoxicity evaluation of benz[e]indole pyrazolyl-substituted amides. Mol. Divers 2024, 28, 1363–1376. [Google Scholar] [CrossRef] [PubMed]
- Du, B.; Liu, X.; Luan, X.; Zhang, W.; Zhuang, C. Structure optimization of an F-indole-chalcone (FC116) on 4-methoxyphenyl group and therapeutic potential against colorectal cancers with low cytotoxicity. Bioorg. Chem. 2023, 135, 106531. [Google Scholar] [CrossRef] [PubMed]
- Veeranna, D.; Ramdas, L.; Ravi, G.; Bujji, S.; Thumma, V.; Ramchander, J. Synthesis of 1,2,3-Triazole Tethered Indole Derivatives: Evaluation of Anticancer Activity and Molecular Docking Studies. ChemistrySelect 2022, 7, e202201758. [Google Scholar] [CrossRef]
- Gaur, A.; Peerzada, M.N.; Khan, N.S.; Ali, I.; Azam, A. Synthesis and Anticancer Evaluation of Novel Indole Based Arylsulfonylhydrazides against Human Breast Cancer Cells. ACS Omega 2022, 7, 42036–42043. [Google Scholar] [CrossRef] [PubMed]
- Seung, K.J.; Keshavjee, S.; Rich, M.L. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb. Perspect. Med. 2015, 5, a017863. [Google Scholar] [CrossRef]
- Mohammed, H.H.H.; Abbas, S.H.; Abdelhafez, E.-S.M.N.; Berger, J.M.; Mitarai, S.; Arai, M.; Abuo-Rahma, G.E.-D.A.A. Synthesis, molecular docking, antimicrobial evaluation, and DNA cleavage assay of new thiadiazole/oxadiazole ciprofloxacin derivatives. Monatsh. Chem. 2019, 150, 1809–1824. [Google Scholar] [CrossRef]
- Mohammed, H.H.H.; Abuo-Rahma, G.E.-D.A.A.; Abbas, S.H.; Abdelhafez, E.-S.M.N. Current Trends and Future Directions of Fluoroquinolones. Curr. Med. Chem. 2019, 26, 3132–3149. [Google Scholar] [CrossRef]
- Mohammed, H.H.H.; Abdelhafez, E.-S.M.N.; Abbas, S.H.; Moustafa, G.A.I.; Hauk, G.; Berger, J.M.; Mitarai, S.; Arai, M.; El-Baky, R.M.A.; Abuo-Rahma, G.E.-D.A. Design, synthesis and molecular docking of new N-4-piperazinyl ciprofloxacin-triazole hybrids with potential antimicrobial activity. Bioorganic Chem. 2019, 88, 102952. [Google Scholar] [CrossRef]
- Dewangan, R.P.; Singh, M.; Ilic, S.; Tam, B.; Akabayov, B. Cell-penetrating peptide conjugates of indole-3-acetic acid-based DNA primase/Gyrase inhibitors as potent anti-tubercular agents against planktonic and biofilm culture of Mycobacterium smegmatis. Chem. Biol. Drug Des. 2021, 98, 722–732. [Google Scholar] [CrossRef]
- Reddyrajula, R.; Etikyala, U.; Manga, V.; Dalimba, U.K. Discovery of 1,2,3-triazole incorporated indole-piperazines as potent antitubercular agents: Design, synthesis, in vitro biological evaluation, molecular docking and ADME studies. Bioorg. Med. Chem. 2024, 98, 117562. [Google Scholar] [CrossRef]
- Bhakhar, K.A.; Vaghela, P.V.; Varakala, S.D.; Chudasma, S.J.; Gajjar, N.D.; Nagar, P.R.; Sriram, D.; Dhameliya, T.M. Indole-2-carboxamides as New Anti-Mycobacterial Agents: Design, Synthesis, Biological Evaluation and Molecular Modeling against mmpL3. ChemistrySelect 2022, 7, e202201813. [Google Scholar] [CrossRef]
- Etchart, R.J.; Rambo, R.S.; Abbadi, B.L.; Sperotto, N.; Neves, C.E.; Silva, F.F.; Dornelles, M.; Duarte, L.; Macchi, F.S.; Perelló, M.A.; et al. Synthesis and Antimycobacterial Activity of 3-Phenyl-1H-indoles. Molecules 2021, 26, 5148. [Google Scholar] [CrossRef] [PubMed]
- Leena, S.S.; Kaul, G.; Akhir, A.; Saxena, D.; Chopra, S.; Deepthi, A. Green synthesis and antibacterial evaluation of spiro fused tryptanthrin-thiopyrano[2,3-b]indole hybrids targeting drug-resistant S. aureus. Bioorg. Chem. 2022, 128, 106046. [Google Scholar] [CrossRef]
- Kuzovlev, A.S.; Zybalov, M.D.; Golovin, A.V.; Gureev, M.A.; Kasatkina, M.A.; Biryukov, M.V.; Belik, A.R.; Silonov, S.A.; Yunin, M.A.; Zigangirova, N.A.; et al. Naphthyl-Substituted Indole and Pyrrole Carboxylic Acids as Effective Antibiotic Potentiators-Inhibitors of Bacterial Cystathionine γ-Lyase. Int. J. Mol. Sci. 2023, 24, 16331. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Z.; Li, W.; Wu, H.; Liu, Z.; Huang, H. Novel photoactivated Indole-pyridine chemotherapeutics with strong antimicrobial and antibiofilm activity toward Staphylococcus aureus. Bioorg. Chem. 2023, 140, 106813. [Google Scholar] [CrossRef] [PubMed]
- Potapov, K.V.; Novikov, R.A.; Novikov, M.A.; Solyev, P.N.; Tomilov, Y.V.; Kochetkov, S.N.; Makarov, A.A.; Mitkevich, V.A. Synthesis of the Indole-Based Inhibitors of Bacterial Cystathionine γ-Lyase NL1-NL3. Molecules 2023, 28, 3568. [Google Scholar] [CrossRef]
- Li, Y.; Kowah, J.A.H.; Jiang, M.; Wu, Y.; Wang, L.; Yang, F. Synthesis, antibacterial activity, and 3D-QASR studies of matrine-indole derivatives as potential antibiotics. Bioorganic Med. Chem. Lett. 2024, 102, 129671. [Google Scholar] [CrossRef]
- Kalatuwawege, I.P.; Gunaratna, M.J.; Udukala, D.N. Synthesis, In Silico Studies, and Evaluation of Syn and Anti Isomers of N-Substituted Indole-3-carbaldehyde Oxime Derivatives as Urease Inhibitors against Helicobacter pylori. Molecules 2021, 26, 6658. [Google Scholar] [CrossRef]
- Ma, J.; Jiang, Y.; Zhuang, X.; Chen, H.; Shen, Y.; Mao, Z.; Rao, G.; Wang, R. Discovery of novel indole and indoline derivatives against Candida albicans as potent antifungal agents. Bioorganic Med. Chem. Lett. 2022, 71, 128826. [Google Scholar] [CrossRef]
- Wu, Y.; Sun, A.; Chen, F.; Zhao, Y.; Zhu, X.; Zhang, T.; Ni, G.; Wang, R. Synthesis, structure-activity relationship and biological evaluation of indole derivatives as anti-Candida albicans agents. Bioorg. Chem. 2024, 146, 107293. [Google Scholar] [CrossRef]
- Kronenberger, T.; Laufer, S.A.; Pillaiyar, T. COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease. Drug Discov. Today 2023, 28, 103579. [Google Scholar] [CrossRef] [PubMed]
- Girgis, A.S.; Panda, S.S.; Kariuki, B.M.; Bekheit, M.S.; Barghash, R.F.; Aboshouk, D.R. Indole-Based Compounds as Potential Drug Candidates for SARS-CoV-2. Molecules 2023, 28, 6603. [Google Scholar] [CrossRef] [PubMed]
- Verzola, M.M.S.A.; de Almeida Marques, D.P.; da Silva, E.B.; Serafim, M.S.M.; Ferreira, R.S.; Fajtová, P.; Kohlhoff, M.; O’Donoghue, A.J.; Maltarollo, V.G.; Coelho-dos-Reis, J.G.A.; et al. Synthesis of indole-based ferulic acid derivatives and in vitro evaluation of antiviral activity against SARS-CoV-2. Med. Chem. Res. 2023, 32, 2256–2267. [Google Scholar] [CrossRef]
- Soleymani, N.; Ahmadi, S.; Shiri, F.; Almasirad, A. QSAR and molecular docking studies of isatin and indole derivatives as SARS 3CLpro inhibitors. BMC Chem. 2023, 17, 32. [Google Scholar] [CrossRef]
- Jayabal, K.; Elumalai, D.; Leelakrishnan, S.; Bhattacharya, S.; Rengarajan, V.; Kannan, T.; Chuang, S.-C. Green and Regioselective Approach for the Synthesis of 3-Substituted Indole Based 1,2-Dihydropyridine and Azaxanthone Derivatives as a Potential Lead for SARS-CoV-2 and Delta Plus Mutant Virus: DFT and Docking Studies. ACS Omega 2022, 7, 43856–43876. [Google Scholar] [CrossRef]
- Geedkar, D.; Kumar, A.; Sharma, P. Synthesis and in silico inhibitory action studies of azo-anchored imidazo[4,5-b]indole scaffolds against the COVID-19 main protease (Mpro). Sci. Rep. 2024, 14, 10419. [Google Scholar] [CrossRef]
- Zhang, R.-H.; Chen, G.-Q.; Wang, W.; Wang, Y.-C.; Zhang, W.-L.; Chen, T.; Xiong, Q.-Q.; Zhao, Y.-L.; Liao, S.-G.; Li, Y.-J.; et al. Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as novel HIV-1 integrase strand transfer inhibitors. RSC Adv. 2024, 14, 9020–9031. [Google Scholar] [CrossRef]
- Wang, Y.-C.; Zhang, W.-L.; Zhang, R.-H.; Liu, C.-H.; Zhao, Y.-L.; Yan, G.-Y.; Liao, S.-G.; Li, Y.-J.; Zhou, M. The Discovery of Indole-2-carboxylic Acid Derivatives as Novel HIV-1 Integrase Strand Transfer Inhibitors. Molecules 2023, 28, 8020. [Google Scholar] [CrossRef]
- Ji, K.; Zhang, G.-N.; Zhao, J.-Y.; Zhu, M.; Wang, M.-H.; Wang, J.-X.; Cen, S.; Wang, Y.-C.; Li, W.-Y. Design, synthesis, and anti-influenza A virus activity evaluation of novel indole containing derivatives of triazole. Bioorg. Med. Chem. Lett. 2022, 64, 128681. [Google Scholar] [CrossRef]
- Nisha; Singh, S.; Sharma, N.; Chandra, R. The indole nucleus as a selective COX-2 inhibitor and anti-inflammatory agent (2011–2022). Org. Chem. Front. 2022, 9, 3624–3639. [Google Scholar] [CrossRef]
- Akhtar, M.; Lai, L.; Tian, T.; Zhang, X.; Cheng, H.; Lin, L. A series of indole-derived γ-hydroxy propiolate esters as potent anti-inflammatory agents: Design, synthesis, in-vitro and in-vivo biological studies. Eur. J. Med. Chem. 2024, 270, 116376. [Google Scholar] [CrossRef]
- Bhatia, R.; Vyas, A.; El-Bahy, S.M.; Hessien, M.M.; Mersal, G.A.M.; Ibrahim, M.M.; Dogra, R.; Kumar, B.; Design, R. Synthesis, Pharmacological and In-silico Investigation of Indole-Functionalized Isoxazoles as Anti-inflammatory Agents. ChemistrySelect 2022, 7, e202200800. [Google Scholar] [CrossRef]
- Faura, G.G.; Wu, B.; Oyelere, A.K.; France, S. Synthetic methodology-enabled discovery of a tunable indole template for COX-1 inhibition and anti-cancer activity. Bioorg. Med. Chem. 2022, 57, 116633. [Google Scholar] [CrossRef]
- Wang, H.; Cui, E.; Li, J.; Ma, X.; Jiang, X.; Du, S.; Qian, S.; Du, L. Design and synthesis of novel indole and indazole-piperazine pyrimidine derivatives with anti-inflammatory and neuroprotective activities for ischemic stroke treatment. Eur. J. Med. Chem. 2022, 241, 114597. [Google Scholar] [CrossRef] [PubMed]
- Zheng, Z.; Li, X.; Chen, P.; Zou, Y.; Shi, X.; Li, X.; Kim, E.Y.; Liao, J.; Yang, J.; Chattipakorn, N.; et al. Design and synthesis optimization of novel diimide indoles derivatives for ameliorating acute lung injury through modulation of NF-κB signaling pathway. Bioorg. Chem. 2023, 136, 106557. [Google Scholar] [CrossRef] [PubMed]
- Chen, T.; Wei, Y.; Zhu, G.; Zhao, H.; Zhang, X. Design, synthesis and structure-activity relationship studies of 4-indole-2-arylaminopyrimidine derivatives as anti-inflammatory agents for acute lung injury. Eur. J. Med. Chem. 2021, 225, 113766. [Google Scholar] [CrossRef]
- Baramaki, I.; Altıntop, M.D.; Arslan, R.; Altınok, F.A.; Özdemir, A.; Dallali, I.; Hasan, A.; Türkmen, N.B. Design, Synthesis, and In Vivo Evaluation of a New Series of Indole-Chalcone Hybrids as Analgesic and Anti-Inflammatory Agents. ACS Omega 2024, 9, 12175–12183. [Google Scholar] [CrossRef]
- Jin, J.; He, H.; Zhang, X.; Wu, R.; Gan, L.; Li, D.; Lu, Y.; Wu, P.; Wong, W.-L.; Zhang, K. The in vitro and in vivo study of oleanolic acid indole derivatives as novel anti-inflammatory agents: Synthesis, biological evaluation, and mechanistic analysis. Bioorg. Chem. 2021, 113, 104981. [Google Scholar] [CrossRef]
- Zhu, Y.; Zhao, J.; Luo, L.; Gao, Y.; Bao, H.; Li, P.; Zhang, H. Research progress of indole compounds with potential antidiabetic activity. Eur. J. Med. Chem. 2021, 223, 113665. [Google Scholar] [CrossRef]
- Ritu; Sharma, P.; Gupta, G.D.; Asati, V. Design, synthesis and antidiabetic study of triazole clubbed indole derivatives as α-glucosidase inhibitors. Bioorg. Chem. 2023, 139, 106750. [Google Scholar] [CrossRef]
- Sayahi, M.H.; Zareei, S.; Halimi, M.; Alikhani, M.; Moazzam, A.; Mohammadi-Khanaposhtani, M.; Mojtabavi, S.; Faramarzi, M.A.; Rastegar, H.; Taslimi, P.; et al. Design, synthesis, in vitro, and in silico anti-α-glucosidase assays of N-phenylacetamide-1,2,3-triazole-indole-2-carboxamide derivatives as new anti-diabetic agents. Sci. Rep. 2024, 14, 15791. [Google Scholar] [CrossRef]
- Niri, D.R.; Sayahi, M.H.; Behrouz, S.; Moazzam, A.; Mojtabavi, S.; Faramarzi, M.A.; Larijani, B.; Rastegar, H.; Mohammadi-Khanaposhtani, M.; Mahdavi, M. Design, synthesis, in vitro, and in silico biological evaluations of coumarin-indole hybrids as new anti-α-glucosidase agents. BMC Chem. 2022, 16, 84. [Google Scholar] [CrossRef] [PubMed]
- Taha, M.; Imran, S.; Salahuddin, M.; Iqbal, N.; Rahim, F.; Uddin, N.; Shehzad, A.; Farooq, R.K.; Alomari, M.; Khan, K.M. Evaluation and docking of indole sulfonamide as a potent inhibitor of α-glucosidase enzyme in streptozotocin -induced diabetic albino wistar rats. Bioorg. Chem. 2021, 110, 104808. [Google Scholar] [CrossRef]
- Solangi, M.; Kanwal; Khan, K.; Saleem, F.; Hameed, S.; Iqbal, J.; Shafique, Z.; Qureshi, U.; Ul-Haq, Z.; Taha, M.; et al. Indole acrylonitriles as potential anti-hyperglycemic agents: Synthesis, α-glucosidase inhibitory activity and molecular docking studies. Bioorganic Med. Chem. 2020, 28, 115605. [Google Scholar] [CrossRef] [PubMed]
- Wu, P.; He, H.; Ma, H.; Tu, B.; Li, J.; Guo, S.; Chen, S.; Cao, N.; Zheng, W.; Tang, X.; et al. Oleanolic acid indole derivatives as novel α-glucosidase inhibitors: Synthesis, biological evaluation, and mechanistic analysis. Bioorg. Chem. 2021, 107, 104580. [Google Scholar] [CrossRef]
- Hu, C.; Liang, B.; Sun, J.; Li, J.; Xiong, Z.; Wang, S.-H.; Xuetao, X. Synthesis and biological evaluation of indole derivatives containing thiazolidine-2,4-dione as α-glucosidase inhibitors with antidiabetic activity. Eur. J. Med. Chem. 2024, 264, 115957. [Google Scholar] [CrossRef]
- Taha, M.; Alrashedy, A.S.; Almandil, N.B.; Iqbal, N.; Anouar, E.H.; Nawaz, M.; Uddin, N.; Chigurupati, S.; Wadood, A.; Rahim, F.; et al. Synthesis of indole derivatives as diabetics II inhibitors and enzymatic kinetics study of α-glucosidase and α-amylase along with their in-silico study. Int. J. Biol. Macromol. 2021, 190, 301–318. [Google Scholar] [CrossRef]
- Jagadeesan, S.; Subramanian, K.; Noor, A.; Basu, R. Indole 3-heterocyclic derivative: A potential antioxidant, antidiabetic agent and their docking study on alpha amylase. J. Mol. Struct. 2023, 1291, 136027. [Google Scholar] [CrossRef]
- Tamura, Y.; Morita, I.; Hinata, Y.; Kojima, E.; Ozasa, H.; Ikemoto, H.; Asano, M.; Wada, T.; Hayasaki-Kajiwara, Y.; Iwasaki, T.; et al. Identification of novel indole derivatives as highly potent AMPK activators with anti-diabetic profiles. Bioorg. Med. Chem. Lett. 2022, 68, 128769. [Google Scholar] [CrossRef]
- Zhao, X.; Yoon, D.-O.; Yoo, J.; Park, H.-J. Structure-Activity Relationship Study and Biological Evaluation of 2-(Disubstituted phenyl)-indole-5-propanoic Acid Derivatives as GPR40 Full Agonists. J. Med. Chem. 2021, 64, 4130–4149. [Google Scholar] [CrossRef]
- Coşar, E.; Dincel, E.; Demiray, S.; Sucularlı, E.; Tüccaroğlu, E.; Ozsoy, N.; Güzeldemirci, N.U. Anticholinesterase activities of novel indole-based hydrazide-hydrazone derivatives: Design, synthesis, biological evaluation, molecular docking study and in silico ADME prediction. J. Mol. Struct. 2021, 1247, 131398. [Google Scholar] [CrossRef]
- Alım, Z.; Shirinzadeh, H.; Kılınç, N.; Dilek, E.; Suzen, S. Assessing Indole Derivative Molecules as Dual Acetylcholinesterase and Butyrylcholinesterase Inhibitors through In Vitro Inhibition and Molecular Modelling Studies. J. Mol. Struct. 2024, 1311, 138276. [Google Scholar] [CrossRef]
- Nerella, A.; Jeripothula, M. Design, synthesis and biological evaluation of novel deoxyvasicinone-indole as multi-target agents for Alzheimer’s disease. Bioorg. Med. Chem. Lett. 2021, 49, 128212. [Google Scholar] [CrossRef] [PubMed]
- Nadeem, M.S.; Khan, J.A.; Kazmi, I.; Rashid, U. Design, Synthesis, and Bioevaluation of Indole Core Containing 2-Arylidine Derivatives of Thiazolopyrimidine as Multitarget Inhibitors of Cholinesterases and Monoamine Oxidase A/B for the Treatment of Alzheimer Disease. ACS Omega 2022, 7, 9369–9379. [Google Scholar] [CrossRef]
- Banoo, R.; Nuthakki, V.K.; Wadje, B.N.; Sharma, A.; Bharate, S.B. Design, synthesis, and pharmacological evaluation of indole-piperidine amides as Blood-brain barrier permeable dual cholinesterase and β-secretase inhibitors. Eur. J. Med. Chem. 2024, 266, 116131. [Google Scholar] [CrossRef]
- Wichur, T.; Pasieka, A.; Godyń, J.; Panek, D.; Góral, I.; Latacz, G.; Honkisz-Orzechowska, E.; Bucki, A.; Siwek, A.; Głuch-Lutwin, M.; et al. Discovery of 1-(phenylsulfonyl)-1H-indole-based multifunctional ligands targeting cholinesterases and 5-HT6 receptor with anti-aggregation properties against amyloid-beta and tau. Eur. J. Med. Chem. 2021, 225, 113783. [Google Scholar] [CrossRef]
- Neshat, N.; Hashmi, Z.; Islam, R.; Aaghaz, S.; Das, S.; Sharma, K.; Ansari, M.; Alam, M.; Shaquiquzzaman, M.; Ansari, M.; et al. Indole-based heterocyclic conjugates: Design, synthesis, in silico studies and cholinesterase inhibition. J. Mol. Struct. 2024, 1319, 139529. [Google Scholar] [CrossRef]
- Cetin, A.; Toptas, M.; Türkan, F. Synthesis, biological evaluation, and bioinformatics analysis of indole analogs on AChE and GST activities. Med. Chem. Res. 2022, 31, 2119–2131. [Google Scholar] [CrossRef]
- Khan, S.; Taha, M.; Rahim, F.; Shah, M.; Ullah, H.; Bahadur, A.; Alrbyawi, H.; Dera, A.; Alahmdi, M.; Pashameah, R.; et al. Synthesis, In Vitro Biological Evaluation and In Silico Molecular Docking Studies of Indole Based Thiadiazole Derivatives as Dual Inhibitor of Acetylcholinesterase and Butyrylchloinesterase. Molecules 2022, 27, 7368. [Google Scholar] [CrossRef]
- Zhou, L.-C.; Liang, Y.-F.; Huang, Y.; Yang, G.-X.; Zheng, L.; Sun, J.-M.; Li, Y.; Zhu, F.-L.; Qian, H.-W.; Wang, R.; et al. Design, Synthesis, and Biological Evaluation of Diosgenin-indole Derivatives as Dual-functional Agents for the Treatment of Alzheimer’s Disease. Eur. J. Med. Chem. 2021, 219, 113426. [Google Scholar] [CrossRef]
- Chiu, Y.-J.; Lin, C.-H.; Lin, C.-Y.; Yang, P.-N.; Lo, Y.-S.; Chen, Y.-C.; Chen, C.-M.; Wu, Y.-R.; Yao, C.-F.; Chang, K.-H.; et al. Investigating Therapeutic Effects of Indole Derivatives Targeting Inflammation and Oxidative Stress in Neurotoxin-Induced Cell and Mouse Models of Parkinson’s Disease. Int. J. Mol. Sci. 2023, 24, 2642. [Google Scholar] [CrossRef] [PubMed]
- Liang, T.; Xie, Z.; Dang, B.; Wang, J.; Zhang, T.; Luan, X.; Lu, T.; Cao, C.; Chen, X. Discovery of indole-piperazine derivatives as selective histone deacetylase 6 inhibitors with neurite outgrowth-promoting activities and neuroprotective activities. Bioorg. Med. Chem. Lett. 2023, 81, 129148. [Google Scholar] [CrossRef] [PubMed]
- Nishikawa-Shimono, R.; Kuwabara, M.; Fujisaki, S.; Matsuda, D.; Endo, M.; Kamitani, M.; Futamura, A.; Nomura, Y.; Yamaguchi-Sasaki, T.; Yabuuchi, T.; et al. Discovery of novel indole derivatives as potent and selective inhibitors of proMMP-9 activation. Bioorg. Med. Chem. Lett. 2024, 97, 129541. [Google Scholar] [CrossRef] [PubMed]
- Pasha, A.; Khan, A.; Ullah, S.; Halim, S.; Alharthy, R.; Anwar, M.; Hussain, J.; Naseer, M.; Kashtoh, H.; Al-Harrasi, A.; et al. Indole-based thiosemicarbazones for neurodegenerative diseases as prolyl oligopeptidase inhibitors. J. Mol. Struct. 2024, 1312, 138666. [Google Scholar] [CrossRef]
- Yi, C.; Xue, Y.; Chen, K.; Wang, T.; Yu, J.; Wang, Z.; Jin, C. Novel difluoromethyl-containing 1-((4-methoxy-3-(piperazin-1-yl)phenyl)sulfonyl)-1H-indole scaffold as potent 5-HT6R antagonists: Design, synthesis, biological evaluation, and early in vivo cognition-enhancing studies. Bioorg. Med. Chem. 2022, 70, 116917. [Google Scholar] [CrossRef]
- Yi, C.; Chen, K.; Liang, H.; Wang, Z.; Wang, T.; Li, K.; Yu, J.; Sun, J.; Jin, C. Novel difluoromethylated 1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-indole derivatives as potent 5-HT6 receptor antagonist with AMDE-improving properties: Design, synthesis, and biological evaluation. Bioorg. Med. Chem. 2022, 71, 116950. [Google Scholar] [CrossRef]
- Danilenko, A.; Volov, A.; Volov, N.; Platonova, Y.; Savilov, S. Design, synthesis and biological evaluation of novel indole-3-carboxylic acid derivatives with antihypertensive activity. Bioorganic Med. Chem. Lett. 2023, 90, 129349. [Google Scholar] [CrossRef]
- Baranwal, G.; Goodlett, B.; Arenaz, C.; Creed, H.; Navaneethabalakrishnan, S.; Rutkowski, J.; Alaniz, R.; Mitchell, B. Indole Propionic Acid Increases T Regulatory Cells and Decreases T Helper 17 Cells and Blood Pressure in Mice with Salt-Sensitive Hypertension. Int. J. Mol. Sci. 2023, 24, 9192. [Google Scholar] [CrossRef]
Drug Name | Chemical Structure | Indication | Mechanism of Action |
---|---|---|---|
Pindolol | Hypertension, angina pectoris [24] | Non-selective beta-blockers decrease heart rate and blood pressure by blocking beta-1 and beta-2 adrenergic receptors [24]. | |
Carvedilol | Hypertension, heart failure, left ventricular dysfunction post-myocardial infarction [25] | Non-selective beta-blockers and alpha-1 blockers reduce heart rate, blood pressure, and myocardial oxygen demand [25]. | |
Oxitriptan | Depression, sleep disorders, appetite suppression [26,27] | Precursor to serotonin; increases serotonin levels in the brain [26]. | |
Sumatriptan | Migraine, cluster headaches [28] | Selective serotonin receptor agonist (5-HT1B/1D) causes vasoconstriction and reduces neurogenic inflammation [28]. | |
Panobinostat | Multiple myeloma [29] | Histone deacetylase inhibitor induces cell cycle arrest and apoptosis in cancer cells [29]. | |
Tropisetron | Nausea and vomiting induced by chemotherapy or surgery [30] | 5-HT3 receptor antagonist blocks serotonin receptors in the central nervous and gastrointestinal tract [30]. | |
Pergolide | Parkinson’s disease [31] | Dopamine receptor agonists stimulate dopamine receptors in the brain [31]. | |
Iptacopan | Paroxysmal nocturnal hemoglobinuria (PNH) [32] | Complement factor B inhibitor prevents the formation of the membrane attack complex [32]. | |
Delavirdine | HIV-1 infection [33] | Non-nucleoside reverse transcriptase inhibitor (NNRTI) inhibits HIV-1 reverse transcriptase [33]. | |
Vilazodone | Major depressive disorder [34] | Selective serotonin reuptake inhibitor (SSRI) and partial agonist at 5-HT1A receptors [34]. | |
Bazedoxifene | Osteoporosis in postmenopausal women [35] | Selective estrogen receptor modulator (SERM) mimics estrogen in bones to maintain bone density [35]. | |
Cabergoline | Hyperprolactinemia, Parkinson’s disease [36,37] | Dopamine receptor agonist inhibits prolactin secretion [36]. | |
Etodolac | Pain and inflammation [38] | Non-steroidal anti-inflammatory drug (NSAID) inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis [38]. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mo, X.; Rao, D.P.; Kaur, K.; Hassan, R.; Abdel-Samea, A.S.; Farhan, S.M.; Bräse, S.; Hashem, H. Indole Derivatives: A Versatile Scaffold in Modern Drug Discovery—An Updated Review on Their Multifaceted Therapeutic Applications (2020–2024). Molecules 2024, 29, 4770. https://doi.org/10.3390/molecules29194770
Mo X, Rao DP, Kaur K, Hassan R, Abdel-Samea AS, Farhan SM, Bräse S, Hashem H. Indole Derivatives: A Versatile Scaffold in Modern Drug Discovery—An Updated Review on Their Multifaceted Therapeutic Applications (2020–2024). Molecules. 2024; 29(19):4770. https://doi.org/10.3390/molecules29194770
Chicago/Turabian StyleMo, Xingyou, Devendra Pratap Rao, Kirandeep Kaur, Roket Hassan, Ahmed S. Abdel-Samea, Sara Mahmoud Farhan, Stefan Bräse, and Hamada Hashem. 2024. "Indole Derivatives: A Versatile Scaffold in Modern Drug Discovery—An Updated Review on Their Multifaceted Therapeutic Applications (2020–2024)" Molecules 29, no. 19: 4770. https://doi.org/10.3390/molecules29194770
APA StyleMo, X., Rao, D. P., Kaur, K., Hassan, R., Abdel-Samea, A. S., Farhan, S. M., Bräse, S., & Hashem, H. (2024). Indole Derivatives: A Versatile Scaffold in Modern Drug Discovery—An Updated Review on Their Multifaceted Therapeutic Applications (2020–2024). Molecules, 29(19), 4770. https://doi.org/10.3390/molecules29194770